Soverign | Tokio X'press

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

FDA Grants Breakthrough Therap

Wednesday August 30th, 2017By Tokio X'press FDA, JPN Daiichi Sankyo

FDA Grants Breakthrough Therap

GS INVESTMENTS,

Wednesday August 30th, 2017By Tokio X'press Holdings, USA GS INVESTMENTS

GS INVESTMENTS,

SHIMADZU CORPORA

Wednesday August 30th, 2017By Tokio X'press JPN, precision

SHIMADZU CORPORA

MITSUBISHI ELECT

MITSUBISHI ELECT

ITOCHU Announces

Wednesday August 30th, 2017By Tokio X'press power generation, JPN, USA itochu

ITOCHU Announces